Avid Bioservices Completes Phase One of Viral Vector Facility Construction
CDMO’s Costa Mesa location can start tackling oncology and rare disease treatment
Avid Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), has officially completed phase one of its new purpose-built, 53,000-square-foot viral vector and current good manufacturing practice (cGMP) facility in Costa Mesa, CA, in eight months. With the site now being open, these viral vectors will be used in the treatment of oncology and rare disease.
The facility was designed and constructed by CRB, who provides sustainable engineering, architecture, construction, and consulting solutions to the life sciences industry.
"Expanding our offerings into viral vectors was a natural adjacency for Avid, as previously explained by our CEO, Nick Green. However, the work really came down to finding a design-build partner with the process, design, and construction expertise to help us deliver a best-in-class facility within a constrained schedule and budget,” notes Mike Alston Jr., director of project engineering for Avid Bioservices. “CRB has done a great job filling this need for Avid and partnering with us to ensure this new facility meets the needs of current and future clients."
The second phase is expected to become operational by mid 2023—upon completion, the facility will feature capacity for adherent and suspension cultures.
